ABSTRACT
Background Tertiary lymphoid structures (TLSs) within the tumor microenvironment have emerged as potential indicators of treatment response to immune checkpoint inhibitors (ICIs). This study aims to explore the association between artificial intelligence (AI)-powered TLS analysis and treatment outcomes in NSCLC patients treated with ICIs.
Methods An AI-powered analyzer, Lunit SCOPE, was developed and trained on H&E-stained whole slide images to quantify TLS. An external cohort of 102 advanced-stage NSCLC patients was utilized to assess the predictive value of TLS.
Results Of 102 patients, 30.3% (31/102) cases were found to contain TLS as determined by the AI analyzer. The AI model achieved an accuracy of 88.2% in identifying the presence of TLS. TLS presence assessed by AI analyzer was associated with significantly favorable progression-free survival (HR 0.49, 95% CI 0.29–0.82, p < 0.01) and overall survival (HR 0.55, 95% CI 0.33–0.92, p = 0.02). The presence of TLS was associated with favorable survival outcomes, independent of PD-L1 status, treatment regimen (ICI monotherapy vs. combination therapy), lines of therapy (first-line vs. second-line and beyond), and tissue harvest site (primary vs. metastatic). The TLS presence enhanced predictive performance when TLS was assessed from WSI obtained from metastatic lesions.
Conclusions To our knowledge, this study is the first to develop an AI model capable of detecting the presence of TLS in WSI, with clinical validation using real-world data demonstrating its independent predictive value of survival outcomes in advanced-stage NSCLC patients receiving immunotherapy.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; Young Kwang Chae has received honorarium from Lunit company; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the local Institutional Review Board of Northwestern Memorial Hospital (STU00207117)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- AI
- artificial intelligence
- ASCO
- American Society of Clinical Oncology
- BP
- biological process
- CA
- cancer area
- CIBERSORT
- Cell-type Identification by Estimating Relative Subsets of RNA Transcripts
- CI
- confidence interval
- CS
- cancer stroma
- DL
- deep learning
- EGFR
- epidermal growth factor receptor
- GSEA
- gene set enrichment analysis
- H&E
- hematoxylin and eosin
- HR
- hazard ratio
- ICI
- immune checkpoint inhibitor
- IHC
- immunohistochemistry
- iTIL
- intratumoral tumor-infiltrating lymphocyte
- IQR
- interquartile range
- LN
- lymph node
- LUAD
- lung adenocarcinoma
- mOS
- median overall survival
- mPFS
- median progression-free survival
- NES
- normalized enrichment score
- NMH
- Northwestern Memorial Hospital
- NSCLC
- non-small cell lung cancer
- ORR
- objective response rate
- OS
- overall survival
- PD-1
- programmed cell death protein 1
- PD-L1
- programmed death-ligand 1
- PFS
- progression-free survival
- RNA
- ribonucleic acid
- sTIL
- stromal tumor-infiltrating lymphocyte
- TGFβ
- transforming growth factor beta
- TIL
- tumor-infiltrating lymphocyte
- TLS
- tertiary lymphoid structure
- TLSP
- TLS proportion
- TMB
- tumor mutational burden
- TME
- tumor microenvironment
- WSI
- whole slide image.
